— Our technology
Enabling cancer immunotherapy through engineered live biotherapeutics
Creating successful immunotherapy in solid tumours
The tumour microenvironment creates multiple constraints to the success of immunotherapy in solid tumours. In a subset of patients, the highly fibrotic stroma can create barriers to immune infiltration leading to immune excluded tumours. Our programmable live therapeutics are engineered to remove these barriers in a safe and targeted way, expanding the benefits of immunotherapies to non-responding cancer patients.
Developing a synthetic biology live biotherapeutic platform
Neobe is developing a synthetic biology live biotherapeutic platform for a safe and targeted remodeling of the microenvironment of solid tumours. Our engineered live biotherapeutics are based on safe therapeutic bacterial strains, with a high safety profile and demonstrated tumour colonizing properties. Through our platform they are engineered with synthetic biosensors for the contained intratumoural release of microenvironment remodeling, enabling a localized breakdown of stromal barriers to immune infiltration.
We currently have two products in the pipeline entering pre-clinical development, targeting solid cancer indications of high unmet clinical need. Contact us to learn more!
Meet our dedicated team of scientists and researchers
Neobe’s leadership has decades of combined experience in cancer biology, advanced therapies and bacterial engineering, supported by recognized leaders in oncology business development. Our world class R&D team is committed to a culture of collaboration and inclusion, working together to bring our engineered LBPs to the clinic.